Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.
• patients with knee osteoarthritis whose inclusion criteria meet the diagnostic criteria for arthritis .
• no drug contraindications .
• aged between 45 and 75 .
• committed to follow the research procedures, And cooperate with the •implementation of the whole process study .
• the patient understands the relevant treatment process .
• the patient has the ability to give informed consent .
• The patient had not recently taken any medication that affected observation.
• the subjects must meet all the inclusion criteria to be eligible to participate in the study .